Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Deborah Autor sold 23,828 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total transaction of $441,532.84. Following the transaction, the insider owned 48,961 shares in the company, valued at approximately $907,247.33. The trade was a 32.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Hims & Hers Health Stock Down 2.5%
NYSE:HIMS traded down $0.43 during trading hours on Wednesday, hitting $17.12. 9,531,665 shares of the stock traded hands, compared to its average volume of 22,172,965. The firm has a market cap of $4.01 billion, a price-to-earnings ratio of -20.63 and a beta of 2.53. The firm has a 50 day moving average price of $27.21 and a 200 day moving average price of $26.59. The company has a current ratio of 0.92, a quick ratio of 0.84 and a debt-to-equity ratio of 3.85. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $40.99.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.03). Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The business had revenue of $890.37 million during the quarter, compared to analysts’ expectations of $893.13 million. During the same period in the prior year, the company posted $0.06 earnings per share. The firm’s revenue was up 48.6% on a year-over-year basis. Equities research analysts anticipate that Hims & Hers Health, Inc. will post -0.21 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of HIMS. Versant Capital Management Inc lifted its holdings in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the period. GK Wealth Management LLC acquired a new position in Hims & Hers Health in the 3rd quarter worth $37,000. Compass Financial Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter worth $50,000. Finally, Integrated Wealth Concepts LLC bought a new position in Hims & Hers Health during the 2nd quarter worth about $147,000. Institutional investors and hedge funds own 63.52% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on HIMS. Truist Financial increased their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a report on Monday, August 24th. Deutsche Bank upped their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Barclays reduced their price objective on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a research note on Friday, September 11th. They set a “neutral” rating and a $32.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a research note on Wednesday, November 4th. Three investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $31.53.
Read Our Latest Stock Analysis on HIMS
Hims & Hers Health News Summary
Here’s some of the latest news about HIMS:
- Neutral Sentiment: Two insiders, including CFO Oluyemi Okupe, sold shares under pre-arranged Rule 10b5-1 trading plans. The sales may draw investor attention, though the planned nature of the transactions makes them less clear as a signal about current business prospects. CFO transaction filing
- Negative Sentiment: The new peptide treatments are not FDA-approved, and the company acknowledged that more remains to be learned about their efficacy. That uncertainty could temper enthusiasm for the launch. Hims & Hers launches new peptide treatments while admitting there’s more to learn about efficacy
- Negative Sentiment: Recent coverage points to pressure from slipping profit and a reported loss of 100,000 subscribers, which may weigh on sentiment even as Hims & Hers adds obesity-drug access and other services. Hims & Hers Stock Fell 32% As Profit Slipped Hims & Hers Lost 100K Subscribers Before Adding Eli Lilly’s $299 Zepbound
About Hims & Hers Health
Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
